Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

Glycoprotein V is a relevant immune target in patients with immune thrombocytopenia.

Vollenberg R, Jouni R, Norris PAA, Burg-Roderfeld M, Cooper N, Rummel MJ, Bein G, Marini I, Bayat B, Burack R, Lazarus AH, Bakchoul T, Sachs UJ.

Haematologica. 2019 Jun;104(6):1237-1243. doi: 10.3324/haematol.2018.211086. Epub 2019 Mar 28.

2.

Prognostic value of circulating Bcl-2/IgH levels in patients with follicular lymphoma receiving first-line immunochemotherapy.

Zohren F, Bruns I, Pechtel S, Schroeder T, Fenk R, Czibere A, Maschmeyer G, Kofahl-Krause D, Niederle N, Heil G, Losem C, Welslau M, Brugger W, Germing U, Kronenwett R, Barth J, Rummel MJ, Haas R, Kobbe G.

Blood. 2015 Sep 17;126(12):1407-14. doi: 10.1182/blood-2015-03-630012. Epub 2015 Aug 3.

3.

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial.

Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Grünhagen U, Losem C, Kofahl-Krause D, Heil G, Welslau M, Balser C, Kaiser U, Weidmann E, Dürk H, Ballo H, Stauch M, Roller F, Barth J, Hoelzer D, Hinke A, Brugger W; Study group indolent Lymphomas (StiL).

Lancet. 2013 Apr 6;381(9873):1203-10. doi: 10.1016/S0140-6736(12)61763-2. Epub 2013 Feb 20. Erratum in: Lancet. 2013 Apr 6;381(9873):1184.

PMID:
23433739
4.

Autoantibody-mediated complement activation on platelets is a common finding in patients with immune thrombocytopenic purpura (ITP).

Najaoui A, Bakchoul T, Stoy J, Bein G, Rummel MJ, Santoso S, Sachs UJ.

Eur J Haematol. 2012 Feb;88(2):167-74. doi: 10.1111/j.1600-0609.2011.01718.x. Epub 2011 Nov 22.

PMID:
21985182
5.

Bendamustine's emerging role in the management of lymphoid malignancies.

Rummel MJ, Gregory SA.

Semin Hematol. 2011 Apr;48 Suppl 1:S24-36. doi: 10.1053/j.seminhematol.2011.03.004. Review.

PMID:
21530769
7.

[Hairy cell leukemia: Part II: therapy with cladribine].

Barth J, Rummel MJ.

Med Monatsschr Pharm. 2009 Jul;32(7):252-60. Review. German.

PMID:
19731753
8.

[Hairy cell leukemia: Part I: disease pattern and common therapy].

Barth J, Rummel MJ.

Med Monatsschr Pharm. 2009 Jul;32(7):249-51. Review. German.

PMID:
19731752
9.

Bendamustine: rebirth of an old drug.

Cheson BD, Rummel MJ.

J Clin Oncol. 2009 Mar 20;27(9):1492-501. doi: 10.1200/JCO.2008.18.7252. Epub 2009 Feb 17. Review. Erratum in: J Clin Oncol. 2009 Jun 10;27(17):2892.

PMID:
19224851
10.

Bendamustine in chronic lymphocytic leukemia and refractory lymphoma.

Rummel MJ.

Semin Hematol. 2008 Jul;45(3 Suppl 2):S7-10. doi: 10.1053/j.seminhematol.2008.07.006. Review.

PMID:
18760709
11.

Remission of a B cell CLL-associated membranoproliferative glomerulonephritis Type I with rituximab and bendamustine.

Bartel C, Obermüller N, Rummel MJ, Geiger H, Hauser IA.

Clin Nephrol. 2008 Apr;69(4):285-9.

PMID:
18397703
12.

Phase I study of a novel pro-apoptotic drug R-etodolac in patients with B-cell chronic lymphocytic leukemia.

Jensen M, Engert A, Weissinger F, Knauf W, Kimby E, Poynton C, Oliff IA, Rummel MJ, Osterborg A.

Invest New Drugs. 2008 Apr;26(2):139-49. Epub 2007 Dec 20.

PMID:
18094935
13.

Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma.

Rummel MJ, Al-Batran SE, Kim SZ, Welslau M, Hecker R, Kofahl-Krause D, Josten KM, Dürk H, Rost A, Neise M, von Grünhagen U, Chow KU, Hansmann ML, Hoelzer D, Mitrou PS.

J Clin Oncol. 2005 May 20;23(15):3383-9.

PMID:
15908650
14.

Treatment of indolent non-Hodgkin's lymphoma with cladribine as single-agent therapy and in combination with mitoxantrone.

Armitage JO, Tobinai K, Hoelzer D, Rummel MJ.

Int J Hematol. 2004 May;79(4):311-21. Review.

PMID:
15218957
15.

Altered apoptosis pathways in mantle cell lymphoma.

Rummel MJ, de Vos S, Hoelzer D, Koeffler HP, Hofmann WK.

Leuk Lymphoma. 2004 Jan;45(1):49-54. Review.

PMID:
15061196
16.

Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer.

Al-Batran SE, Atmaca A, Hegewisch-Becker S, Jaeger D, Hahnfeld S, Rummel MJ, Seipelt G, Rost A, Orth J, Knuth A, Jaeger E.

J Clin Oncol. 2004 Feb 15;22(4):658-63.

PMID:
14966088
17.

Reduced-dose cladribine (2-CdA) plus mitoxantrone is effective in the treatment of mantle-cell and low-grade non-Hodgkin's lymphoma.

Rummel MJ, Chow KU, Karakas T, Jäger E, Mezger J, von Grünhagen U, Schalk KP, Burkhard O, Hansmann ML, Ritzel H, Bergmann L, Hoelzer D, Mitrou PS.

Eur J Cancer. 2002 Sep;38(13):1739-46.

PMID:
12175690
18.

Bendamustine in the treatment of non-Hodgkin's lymphoma: results and future perspectives.

Rummel MJ, Mitrou PS, Hoelzer D.

Semin Oncol. 2002 Aug;29(4 Suppl 13):27-32. Review.

PMID:
12170430
19.

In vitro studies with bendamustine: enhanced activity in combination with rituximab.

Rummel MJ, Chow KU, Hoelzer D, Mitrou PS, Weidmann E.

Semin Oncol. 2002 Aug;29(4 Suppl 13):12-4.

PMID:
12170426
20.

Induction of apoptosis by cladribine (2-CdA), gemcitabine and other chemotherapeutic drugs on CD34+/CD38+ and CD34+/CD38- hematopoietic progenitor cells: selective effects of doxorubicin and 2-CdA with protection of immature cells.

Chow KU, Boehrer S, Bojunga J, Stieler M, Rummel MJ, Fauth F, Schneider B, Martin H, Hoelzer D, Weidmann E, Mitrou PS.

Leuk Lymphoma. 2002 Feb;43(2):377-84.

PMID:
11999573
21.

Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.

Chow KU, Sommerlad WD, Boehrer S, Schneider B, Seipelt G, Rummel MJ, Hoelzer D, Mitrou PS, Weidmann E.

Haematologica. 2002 Jan;87(1):33-43.

22.

Treatment of aggressive, or progressing indolent peripheral T- and NK-cell neoplasias by combination of fludarabine, cyclophosphamide and doxorubicine.

Weidmann E, Boehrer S, Chow KU, Engels K, Harder L, Hinz T, Janssen O, Kriener S, Rummel MJ, Siebert R, Kabelitz D, Hansmann ML, Hoelzer D, Mitrou PS; Study Group Peripheral T- and NK-Cell Neoplasias.

Onkologie. 2001 Apr;24(2):162-4.

PMID:
11441297
23.
24.

Induction of apoptosis by 2-chloro-2'deoxyadenosine (2-CdA) alone and in combination with other cytotoxic drugs: synergistic effects on normal and neoplastic lymphocytes by addition of doxorubicin and mitoxantrone.

Chow KU, Rummel MJ, Weidmann E, Ries J, Jantschke P, Boehrer S, Pourebrahim F, Napieralski S, Stein J, Martin H, Hoelzer D, Mitrou PS.

Leuk Lymphoma. 2000 Feb;36(5-6):559-67.

PMID:
10784401
25.

Intermittent 2-hour-infusion of cladribine as first-line therapy or in first relapse of progressive advanced low-grade and mantle cell lymphomas.

Rummel MJ, Chow KU, Jäger E, Leimer L, Hossfeld DK, Bergmann L, Peters HD, Hansmann ML, Meyer A, Hoelzer D, Mitrou PS.

Leuk Lymphoma. 1999 Sep;35(1-2):129-38.

PMID:
10512170
26.

Fludarabine and epirubicin in the treatment of chronic lymphocytic leukaemia: a German multicenter phase II study.

Rummel MJ, Käfer G, Pfreundschuh M, Jäger E, Reinhardt U, Mitrou PS, Hoelzer D, Bergmann L.

Ann Oncol. 1999 Feb;10(2):183-8.

PMID:
10093687
27.

Treatment of mantle-cell lymphomas with intermittent two-hour infusion of cladribine as first-line therapy or in first relapse.

Rummel MJ, Chow KU, Jäger E, Hossfeld DK, Bergmann L, Peters HD, Hansmann ML, Meyer A, Hoelzer D, Mitrou PS.

Ann Oncol. 1999 Jan;10(1):115-7.

PMID:
10076731

Supplemental Content

Loading ...
Support Center